sertralineWhat was measured
Measured, with no finding
924 endpoints
Show what was measuredHide what was measured
abdominal pain
increases, p = 0.03, n = 55
abdominal pain than imipramine (OR 4.13, 95% CI 1.12 to 15.25, P = 0.03; 1 trial, 55 participants)
PMID 20393946 · one of two readings recorded this
agitation/anxiety
increases, p = 0.02, n = 160
nefazodone (OR 4.71, 95% CI 1.29 to 17.24, P = 0.02; 1 trial, 160 participants)
PMID 20393946 · one of two readings recorded this
anorgasmia
decreases, p = 0.03, n = 353
anorgasmia (OR 0.19, 95% CI 0.04 to 0.89, p = 0.03; 1 trial, 353 participants
PMID 20393946 · one of two readings recorded this
appetite increase
decreases, p = 0.007, n = 263
appetite increase than amitriptyline (OR 0.06, 95% CI 0.01 to 0.45, P = 0.007; 1 trial, 263 participants
PMID 20393946 · one of two readings recorded this
appetite increase
decreases, p = 0.0002, n = 596
appetite increase (OR 0.20, 95% CI 0.09 to 0.46, p = 0.0002; 2 trials, 596 participants
PMID 20393946 · one of two readings recorded this
appetite loss/anorexia
increases, p = 0.009, n = 539
appetite loss/anorexia (OR 7.14, 95% CI 1.63 to 31.18, P = 0.009; 2 trials, 539 participants
PMID 20393946 · one of two readings recorded this
constipation
decreases, p = 0.00001, n = 1158
amitriptyline (OR 0.37, 95% CI 0.25 to 0.55, P<0.00001; 6 trials, 1158 participants)
PMID 20393946 · one of two readings recorded this
constipation
decreases, p = 0.0008, n = 304
clomipramine (OR 0.18, 95% CI 0.07 to 0.49, P = 0.0008; 3 trials, 304 participants)
PMID 20393946 · one of two readings recorded this
constipation
decreases, p = 0.03, n = 487
imipramine (OR 0.17, 95% CI 0.03 to 0.87, P = 0.03; 4 trials, 487 participants)
PMID 20393946 · one of two readings recorded this
constipation
decreases, p = 0.0002, n = 210
nortriptyline (OR 0.28, 95% CI 0.14 to 0.54, P = 0.0002; 1 trial, 210 participants)
PMID 20393946 · one of two readings recorded this
constipation
decreases, p = 0.0002, n = 545
paroxetine (OR 0.31, 95% CI 0.16 to 0.58, P = 0.0002; 2 trials, 545 participants)
PMID 20393946 · one of two readings recorded this
constipation
decreases, p = 0.04, n = 89
venlafaxine (OR 0.05, 95% CI 0.00 to 0.85, P = 0.04; 1 trial, 89 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.0005, n = 779
amitriptyline (OR 11.32, 95% CI 2.90 to 44.18, P = 0.0005; 3 trials, 779 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.005, n = 727
bupropion (OR 3.88, 95% CI 1.50 to 10.07, P = 0.005; 3 trials, 727 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.02, n = 198
clomipramine (OR 4.30, 95% CI 1.28 to 14.44, P = 0.02; 2 trials, 198 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.007, n = 489
escitalopram (OR 2.10, 95% CI 1.22 to 3.61, P = 0.007; 2 trials, 489 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.001, n = 314
hypericum (OR 2.30, 95% CI 1.39 to 3.80, P = 0.001; 2 trials, 314 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.004, n = 398
imipramine (OR 6.75, 95% CI 1.82 to 24.97, P = 0.004; 3 trials, 398 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.0009, n = 596
mirtazapine (OR 2.74, 95% CI 1.52 to 4.97, P = 0.0009; 2 trials, 596 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.04, n = 210
nortriptyline (OR 2.17, 95% CI 1.02 to 4.64, P = 0.04; 1 trial, 210 participants)
PMID 20393946 · one of two readings recorded this
diarrhoea
increases, p = 0.0001, n = 545
paroxetine (OR 2.51, 95% CI 1.66 to 3.80, P<0.0001; 2 trials, 545 participants)
PMID 20393946 · one of two readings recorded this
dizziness
decreases, p = 0.01, n = 1158
dizziness than amitriptyline (OR 0.61, 95% CI 0.42 to 0.89, P = 0.01; 6 trials, 1158 participants)
PMID 20393946 · one of two readings recorded this
dizziness
decreases, p = 0.006, n = 398
imipramine (OR 0.46, 95% CI 0.26 to 0.80, P = 0.006; 3 trials, 398 participants)
PMID 20393946 · one of two readings recorded this
dizziness
decreases, p = 0.0003, n = 160
dizziness (OR 0.17, 95% CI 0.06 to 0.44, p = 0.0003; 1 trial, 160 participants
PMID 20393946 · one of two readings recorded this
dropout due to any cause
increases, p = 0.04, n = 727
bupro-pion for discontinuation due to any cause (OR 1.42, 95% CI 1.02 to 1.99, p = 0.04; 3 studies, 727 participants)
PMID 20393946 · one of two readings recorded this
dropout due to any cause
decreases, p = 0.03, n = 641
fewer patients allocated to sertraline withdrawing from studies than those allocated to imipramine for discontinuation due to any cause (OR 0.62, 95% CI 0.40 to 0.96, p = 0.03; 5 studies, 641 participants)
PMID 20393946 · one of two readings recorded this
dropout due to any cause
decreases, p = 0.05, n = 596
mirtazapine for discontinuation due to any cause (OR 0.68, 95% CI 0.47 to 0.99, p = 0.05; 2 studies, 596 participants)
PMID 20393946 · one of two readings recorded this
dropout due to side effects
no effect, p = 0.06, n = 1457
the difference between sertraline and amitriptyline was in favour of sertraline (OR 0.74, 95% CI 0.55 to 1.01, P = 0.06; 7 studies, 1457 participants)
PMID 20393946 · one of two readings recorded this
dropout due to side effects
decreases, p = 0.06, n = 596
mirtazapine (OR 0.35, 95% CI 0.17 to 0.74, p = 0.06; 2 studies, 596 participants)
PMID 20393946 · one of two readings recorded this
dropout due to side effects
decreases, p = 0.04, n = 311
fewer patients allocated to sertraline withdrew from study than paroxetine for discontinuation due to side effects (OR 0.28, 95% CI 0.08 to 0.96, p = 0.04; 3 studies, 311 participants)
PMID 20393946 · one of two readings recorded this
dropout due to side effects
decreases, p = 0.001, n = 611
venlafaxine (OR 0.33, 95% CI 0.17 to 0.64, p = 0.001; 5 studies, 611 participants)
PMID 20393946 · one of two readings recorded this
dry mouth
decreases, p = 0.00001, n = 1158
amitriptyline (OR 0.16, 95% CI 0.11 to 0.24, P<0.00001; 6 trials, 1158 participants)
PMID 20393946 · one of two readings recorded this
dry mouth
decreases, p = 0.01, n = 304
clomipramine (OR 0.30, 95% CI 0.12 to 0.78, P = 0.01; 3 trials, 304 participants)
PMID 20393946 · one of two readings recorded this
dry mouth
decreases, p = 0.0001, n = 487
imipramine (OR 0.16, 95% CI 0.06 to 0.40, P = 0.0001; 4 trials, 487 participants)
PMID 20393946 · one of two readings recorded this
dry mouth
no effect, p = 0.05, n = 64
this difference was in favour of sertraline (OR 0.20, 95% CI 0.04 to 1.03, P = 0.05; 1 study, 64 participants)
PMID 20393946 · one of two readings recorded this
dry mouth
decreases, p = 0.00001, n = 210
nortriptyline (OR 0.22, 95% CI 0.12 to 0.39, P<0.00001; 1 trial, 210 participants)
PMID 20393946 · one of two readings recorded this
dry mouth
decreases, p = 0.003, n = 49
reboxetine (OR 0.04, 95% CI 0.00 to 0.34, P = 0.003; 1 trial, 49 participants)
PMID 20393946 · one of two readings recorded this
dry mouth
decreases, p = 0.006, n = 89
venlafaxine (OR 0.02, 95% CI 0.00 to 0.33, P = 0.006; 1 trial, 89 participants)
PMID 20393946 · one of two readings recorded this
ejaculation disorder
decreases, p = 0.0009, n = 545
ejaculation disorder (OR 0.29, 95% CI 0.14 to 0.60, p = 0.0009; 2 trials, 545 participants
PMID 20393946 · one of two readings recorded this
fatigue
decreases, p = 0.004, n = 596
fatigue (OR 0.44, 95% CI 0.25 to 0.77, p = 0.004; 2 trials, 596 participants
PMID 20393946 · one of two readings recorded this
gastrointestinal symptoms or dyspepsia
increases, p = 0.003, n = 250
gastrointestinal symptoms or dyspepsia (OR 3.54, 95% CI 1.52 to 8.23, p = 0.003; 1 trial, 250 participants
PMID 20393946 · one of two readings recorded this
gastrointestinal symptoms
decreases, p = 0.005, n = 77
desipramine (OR 0.24, 95% CI 0.09 to 0.65, P = 0.005; 1 trial, 77 participants
PMID 20393946 · one of two readings recorded this
headache
increases, p = 0.04, n = 1090
headache (OR 1.60, 95% CI 1.03 to 2.48, P = 0.04; 5 trials, 1090 participants
PMID 20393946 · one of two readings recorded this
headache
increases, p = 0.04, n = 596
headache (OR 1.53, 95% CI 1.01 to 2.30, p = 0.04; 2 trials, 596 participants
PMID 20393946 · one of two readings recorded this
increased sweating
increases, p = 0.002, n = 727
increased sweating (OR 3.99, 95% CI 1.68 to 9.45, p = 0.002; 2 trials, 727 participants
PMID 20393946 · one of two readings recorded this
increased sweating
increases, p = 0.01, n = 314
increased sweating (OR 1.97, 95% CI 1.15 to 3.38, p = 0.01; 2 trials, 314 participants
PMID 20393946 · one of two readings recorded this
increased sweating
increases, p = 0.04, n = 259
increased sweating (OR 2.44, 95% CI 1.05 to 5.67, p = 0.04; 2 trials, 259 participants
PMID 20393946 · one of two readings recorded this
increased sweating
decreases, p = 0.05, n = 49
increased sweating (OR 0.05, 95% CI 0.00 to 0.94, p = 0.05; 1 trial, 49 participants
PMID 20393946 · one of two readings recorded this
insomnia
increases, p = 0.002, n = 802
higher rate of participants experiencing insomnia than amitriptyline (OR 2.29, 95% CI 1.37 to 3.83, P = 0.002; 3 trials, 802 participants)
PMID 20393946 · one of two readings recorded this
insomnia
increases, p = 0.02, n = 596
insomnia than mirtazapine (OR 2.72, 95% CI 1.15 to 6.43, P = 0.02; 2 trials, 596 participants)
PMID 20393946 · one of two readings recorded this
libido decrease
increases, p = 0.03, n = 346
libido decrease (OR 5.44, 95% CI 1.17 to 25.19, p = 0.03; 1 trial, 346 participants
PMID 20393946 · one of two readings recorded this
mean change in depressive symptoms
decreases, p = 0.009, n = 1172
Sertraline was found to be less efficacious than amitriptyline in reduction of depressive symptoms (SMD 0.18, 95% CI 0.04 to 0.32, p = 0.009; 7 studies, 1172 participants)
PMID 20393946 · one of two readings recorded this
nausea
increases, p = 0.00001, n = 1090
amitriptyline (OR 4.90, 95% CI 3.09 to 7.76, P<0.00001; 5 trials, 1090 participants)
PMID 20393946 · one of two readings recorded this
nausea
increases, p = 0.02, n = 727
bupropion (OR 2.14, 95% CI 1.12 to 4.08, P = 0.02; 3 trials, 727 participants)
PMID 20393946 · one of two readings recorded this
nausea
increases, p = 0.003, n = 314
hypericum (OR 3.43, 95% CI 1.52 to 7.76, P = 0.003; 2 trials, 314 participants)
PMID 20393946 · one of two readings recorded this
nausea
increases, p = 0.01, n = 487
imipramine (OR 2.68, 95% CI 1.26 to 5.73, P = 0.01 4 trials, 487 participants)
PMID 20393946 · one of two readings recorded this
nausea
increases, p = 0.00001, n = 596
mirtazapine (OR 3.68, 95% CI 2.10 to 6.45, P<0.00001; 2 trials, 596 participants)
PMID 20393946 · one of two readings recorded this
nausea
increases, p = 0.02, n = 210
nortriptyline (OR 2.42, 95% CI 1.14 to 5.13, P = 0.02; 1 trial, 210 participants)
PMID 20393946 · one of two readings recorded this
neurological problems (peripheral and central nervous system)
decreases, p = 0.04, n = 309
amitriptyline (OR 0.31, 95% CI 0.10 to 0.95, P = 0.04; 2 trials, 309 participants)
PMID 20393946 · one of two readings recorded this
neurological problems (peripheral and central nervous system)
decreases, p = 0.01, n = 40
clomipramine (OR 0.11, 95% CI 0.02 to 0.61, P = 0.01; 1 trial, 40 participants)
PMID 20393946 · one of two readings recorded this
oftalmological problems
increases, p = 0.05, n = 62
oftalmological problems (OR 8.96, 95% CI 1.05 to 76.74, p = 0.05; 1 trial, 62 participants
PMID 20393946 · one of two readings recorded this
pain
decreases, p = 0.05, n = 241
pain (OR 0.19, 95% CI 0.04 to 0.09, P = 0.05; 1 trial, 241 participants)
PMID 20393946 · one of two readings recorded this
patients experiencing at least one side effect
decreases, p = 0.01, n = 999
Patients allocated to sertraline had a fewer rate of adverse events than amitriptyline (OR 0.59, 95% CI 0.39 to 0.89, p = 0.01; 5 studies, 999 participants)
PMID 20393946 · one of two readings recorded this
patients experiencing at least one side effect
increases, p = 0.03, n = 489
higher rate of adverse events than escitalopram (OR 1.76, 95% CI 1.06 to 2.94, p = 0.03; 2 studies, 489 participants)
PMID 20393946 · one of two readings recorded this
patients experiencing at least one side effect
decreases, p = 0.00001, n = 209
imipramine (OR 0.17, 95% CI 0.09 to 0.32, P<0.00001; 2 studies, 209 participants)
PMID 20393946 · one of two readings recorded this
remission
increases, p = 0.05, n = 482
There was evidence that sertraline was more effective than imipramine (OR 0.67, 95% CI 0.45 to 0.99, p = 0.05; 3 studies, 482 participants)
PMID 20393946 · one of two readings recorded this
remission
decreases, p = 0.008, n = 596
sertraline was less effective than mirtazapine (OR 1.92, 95% CI 1.18 to 3.13, p = 0.008; 2 studies, 596 participants)
PMID 20393946 · one of two readings recorded this
sexual problems
increases, p = 0.0005, n = 259
sexual problems (OR 3.56, 95% CI 1.74 to 7.30, P = 0.0005; 2 trials, 259 participants
PMID 20393946 · one of two readings recorded this
sexual problems
increases, p = 0.02, n = 90
sexual problems (OR 4.00, 95% CI 1.31 to 12.23, p = 0.02; 1 trial, 90 participants
PMID 20393946 · one of two readings recorded this
sleepiness/drowsiness
decreases, p = 0.00001, n = 1090
lower rate of participants experiencing sleepiness than amitriptyline (OR 0.27, 95% CI 0.19 to 0.40, P<0.00001; 5 trials, 1090 participants)
PMID 20393946 · one of two readings recorded this
sleepiness/drowsiness
increases, p = 0.00001, n = 727
bupropion (OR 5.10, 95% CI 2.53 to 10.31, P<0.00001; 3 trials, 727 participants)
PMID 20393946 · one of two readings recorded this
sleepiness/drowsiness
decreases, p = 0.00001, n = 596
mirtazapine (OR 0.33, 95% CI 0.20 to 0.54, P<0.00001; 2 trials, 596 participants)
PMID 20393946 · one of two readings recorded this
sweating increase
increases, p = 0.05, n = 346
sweating increase (OR 4.86, 95% CI 1.04 to 22.85, p = 0.05; 1 trial, 346 participants
PMID 20393946 · one of two readings recorded this
sweating increase
increases, p = 0.04, n = 160
sweating increase (OR 3.01, 95% CI 1.03 to 8.79, p = 0.04; 1 trial, 160 participants
PMID 20393946 · one of two readings recorded this
treatment response rate (at least 50% reduction on HAM-D or MADRS), remission, mean change in depression score, dropout and side effects, sertraline versus other antidepressants
increases, OR 0.73, 95% CI 0.59 to 0.92 versus fluoxetine, p = 0.007
Not recorded as a finding: the comparison was against another active treatment
There was evidence that sertraline was more effective than fluoxetine (OR 0.73, 95% CI 0.59 to 0.92, p = 0.007; 8 studies, 1352 participants) (see Figure 10).
PMID 20393946 · one of two readings recorded this
treatment response
no effect, p = 0.07, n = 1345
the difference between sertraline and amitriptyline was in favour of the latter (OR 1.23, 95% CI 0.99 to 1.52, p = 0.07; 7 studies, 1345 participants)
PMID 20393946 · one of two readings recorded this
treatment response
increases, p = 0.007, n = 1352
There was evidence that sertraline was more effective than fluoxetine (OR 0.73, 95% CI 0.59 to 0.92, p = 0.007; 8 studies, 1352 participants)
PMID 20393946 · one of two readings recorded this
treatment response
decreases, p = 0.05, n = 596
sertraline was less effective than mirtazapine (OR 1.40, 95% CI 1.00 to 1.94, p = 0.05; 2 studies, 596 participants)
PMID 20393946 · one of two readings recorded this
tremor
decreases, p = 0.03, n = 545
tremor (OR 0.55, 95% CI 0.32 to 0.94, p = 0.03, 2 trials, 545 participants
PMID 20393946 · one of two readings recorded this
urinary problems
decreases, p = 0.02, n = 353
urinary problems than paroxetine (OR 0.09, 95% CI 0.01 to 0.68, P = 0.02; 1 trial, 353 participants)
PMID 20393946 · one of two readings recorded this
weight gain
decreases, p = 0.00001, n = 596
weight gain (OR 0.18, 95% CI 0.09 to 0.37, p<0.00001; 2 trials, 596 participants
PMID 20393946 · one of two readings recorded this
correlation between maternal and infant serum desmethylsertraline concentration
increases, Fisher's Z=0.391, 95% CI (0.071, 0.711), p = 0.017
Maternal and infant desmethylsertraline levels were significantly correlated in these studies [Fisher's Z=0.391, p=0.017, 95% CI (0.071, 0.711)] and zero was not included in the confidence interval.
PMID 25589155 · both readings recorded this
correlation between maternal and infant serum sertraline concentration in breastfeeding mother-infant dyads, Fisher's Z transformed Pearson correlation
no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639
Not recorded as a finding: this platform holds no node for the endpoint
The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.
PMID 25589155 · one of two readings recorded this
correlation between maternal and infant serum sertraline concentration in breastfeeding mother-infant dyads, meta-analytic Fisher's Z
no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639
Not recorded as a finding: this platform holds no node for the endpoint
The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.
PMID 25589155 · one of two readings recorded this
correlation between maternal and infant serum sertraline concentration
no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639
The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.
PMID 25589155 · both readings recorded this
correlation between maternal and infant serum sertraline+desmethylsertraline sum concentration
increases, Fisher's Z=0.367, 95% CI (0.080, 0.654), p = 0.012
The sum of sertraline and desmethylsertraline was significantly correlated between mothers and infants in these studies [Fisher's Z=0.367, p=0.012, 95% CI (0.080, 0.654)] and zero was not included in the confidence interval.
PMID 25589155 · one of two readings recorded this
Correlation between maternal and infant serum sum of sertraline plus desmethylsertraline concentration
increases, Fisher's Z=0.367, 95% CI (0.080, 0.654), p = 0.012
The sum of sertraline and desmethylsertraline was significantly correlated between mothers and infants in these studies [Fisher’s Z=0.367, p=0.012, 95% CI (0.080, 0.654)] and zero was not included in the confidence interval.
PMID 25589155 · one of two readings recorded this
atrial and/or ventricular septal defects
increases
atrial and/or ventricular septal defects (OR = 1.36, 95% CI = 1.06-1.76; I2 = 62.2%; n = 8)
PMID 27770542 · one of two readings recorded this
cardiovascular-related malformations
increases
infant cardiovascular-related malformations (OR = 1.36; 95% CI = 1.06-1.74; I2 = 64.4%; n = 12)
PMID 27770542 · one of two readings recorded this
congenital anomalies of the digestive system
no effect
digestive system (OR = 1.23; 95% CI = 0.76-1.98; I2 = 0%; n = 5)
PMID 27770542 · one of two readings recorded this
congenital anomalies of the eye, ear, face and neck
no effect
eye, ear, face and neck (OR = 1.08; 95% CI = 0.33-3.55; I2 = 32.1%; n = 3)
PMID 27770542 · one of two readings recorded this
congenital anomalies of the musculoskeletal system
no effect
musculoskeletal system (OR = 0.97; 95% CI = 0.69-1.36; I2 = 0%; n = 5)
PMID 27770542 · one of two readings recorded this
congenital anomalies of the nervous system
no effect
congenital anomalies of the nervous system (OR = 1.39; 95% CI = 0.83-2.32; I2 = 0%; n = 5)
PMID 27770542 · one of two readings recorded this
congenital anomalies of the urogenital system
no effect
urogenital system (OR = 1.03; 95% CI = 0.73-1.46; I2 = 0%; n = 5)
PMID 27770542 · one of two readings recorded this
adverse events
no effect, RR 0.94; 95% CI 0.83-1.06, p = 0.33
no significant difference between sertraline and control groups in the morbidity of adverse events (RR 0.94; 95% CI 0.83-1.06; P = .33 >0.05).
PMID 30544429 · one of two readings recorded this
gastrointestinal upset (adverse event)
increases, RR 2.71, 95% CI 1.39 to 5.28, p = 0.004
Among them, a significant increased risk of gastrointestinal upset was observed in pooled results of 8 studies (RR 2.71, 95%CI 1.39 to 5.28, P =.004).
PMID 31169738 · one of two readings recorded this
Gastrointestinal upset incidence (adverse event)
increases, RR 2.71, 95% CI 1.39 to 5.28, p = 0.004
Among them, a significant increased risk of gastrointestinal upset was observed in pooled results of 8 studies (RR 2.71, 95%CI 1.39 to 5.28, P =.004).
PMID 31169738 · one of two readings recorded this
intravaginal ejaculation latency time (IELT), meta-analysed as standardised mean difference across trials of sertraline versus placebo/blank control
increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830
Not recorded as a finding: this platform holds no node for the endpoint
Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).
PMID 31169738 · one of two readings recorded this
intravaginal ejaculation latency time (IELT), patient-timed, meta-analytically pooled as SMD
increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830
Not recorded as a finding: this platform holds no node for the endpoint
Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).
PMID 31169738 · one of two readings recorded this
intravaginal ejaculation latency time (IELT)
increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830
Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).
PMID 31169738 · both readings recorded this
patient sexual satisfaction rate
increases, SMD 2.20, 95% CI 1.57 to 2.84
Patients' sexual satisfaction rates were evaluated by 6, 7, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved patients' sexual satisfaction rates (SMD 2.20, 95%CI 1.57 to 2.84, P <.00001).
PMID 31169738 · one of two readings recorded this
Patients' sexual satisfaction rate (IIEF items)
increases, SMD 2.20, 95% CI 1.57 to 2.84
Patients’ sexual satisfaction rates were evaluated by 6, 7, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved patients’ sexual satisfaction rates (SMD 2.20, 95%CI 1.57 to 2.84, P <.00001).
PMID 31169738 · one of two readings recorded this
spouse sexual satisfaction rate
increases, SMD 2.27, 95% CI 1.44 to 3.09
Spouses' sexual satisfaction rates were evaluated by 6, 6, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved spouses' sexual satisfaction rates (SMD 2.27, 95%CI 1.44 to 3.09, P <.00001).
PMID 31169738 · one of two readings recorded this
Spouses' sexual satisfaction rate (IIEF items)
increases, SMD 2.27, 95% CI 1.44 to 3.09
Spouses’ sexual satisfaction rates were evaluated by 6, 6, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved spouses’ sexual satisfaction rates (SMD 2.27, 95%CI 1.44 to 3.09, P <.00001).
PMID 31169738 · one of two readings recorded this
ANCOVA effect of group on baseline EFT interference (bupropion responders, non-responders, controls)
unclear, p = 0.073
F(2,64) = 2.73, p = 0.073, partial η2 = 0.079
PMID 33213541 · one of two readings recorded this
ANCOVA effect of group on baseline response bias (bupropion responders, non-responders, controls)
modulates, p = 0.002
F(2,67) = 6.99, p = 0.002, partial η2 = 0.173
PMID 33213541 · one of two readings recorded this
ANCOVA effect of group on baseline verbal fluency (bupropion responders, non-responders, controls)
modulates, p = 0.003
F(2,76) = 6.20, p = 0.003, partial η2 = 0.140
PMID 33213541 · one of two readings recorded this
ANCOVA effect of group on early ABRT change (placebo responders, non-responders, controls)
modulates, p = 0.039
F(2,144) = 3.32, p = 0.039, partial η2 = 0.044
PMID 33213541 · one of two readings recorded this
ANCOVA effect of group on early CRT change (placebo responders, non-responders, controls)
modulates, p = 0.008
F(2,157) = 4.94, p = 0.008, partial η2 = 0.059
PMID 33213541 · one of two readings recorded this
baseline EFT interference, bupropion responders vs non-responders (post-hoc)
unclear, p = 0.089
t(35) = 2.22, p = 0.089, Cohen’s d = 0.74
PMID 33213541 · one of two readings recorded this
baseline EFT interference, controls vs bupropion non-responders (post-hoc)
no effect, p = 0.71
t(58) = 0.38, p = 0.71, Cohen’s d = 0.10
PMID 33213541 · one of two readings recorded this
baseline EFT interference, controls vs bupropion responders (post-hoc)
no effect, p = 0.134
t(50) = −2.05, p = 0.134, Cohen’s d = 0.65
PMID 33213541 · one of two readings recorded this
baseline response bias, bupropion non-responders vs controls (post-hoc)
decreases, p = 0.005
t(59) = 3.27, p = 0.005, Cohen’s d = 0.86
PMID 33213541 · one of two readings recorded this
baseline response bias, bupropion non-responders vs responders (post-hoc)
decreases, p = 0.006
t(37) = 3.22, p = 0.006, Cohen’s d = 1.00
PMID 33213541 · one of two readings recorded this
baseline response bias, bupropion responders vs controls (post-hoc)
no effect, p = 0.56
t(53) = 0.585, p = 0.56, Cohen’s d = 0.16
PMID 33213541 · one of two readings recorded this
baseline verbal fluency, bupropion non-responders vs controls (post-hoc)
decreases, p = 0.003
t(64) = −3.45, p = 0.003, Cohen’s d = 0.88
PMID 33213541 · one of two readings recorded this
baseline verbal fluency, bupropion non-responders vs responders (post-hoc)
decreases, p = 0.074
t(41) = −2.29, p = 0.074, Cohen’s d = 0.71
PMID 33213541 · one of two readings recorded this
baseline verbal fluency, bupropion responders vs controls (post-hoc)
no effect, p = 0.62
t(56) = 0.505, p = 0.62, Cohen’s d = 0.15
PMID 33213541 · one of two readings recorded this
difference in response prediction by baseline ABRT, sertraline vs placebo
unclear, p = 0.088
B = −0.52, 95% CI = −1.13 to 0.07, p = 0.088
PMID 33213541 · one of two readings recorded this
difference in response prediction by baseline ABRT, simpler model
no effect, p = 0.553
B = −0.14, 95% CI = −0.60 to 0.32, p = 0.553
PMID 33213541 · one of two readings recorded this
difference in response prediction by baseline CRT, placebo vs sertraline
modulates, p = 0.01
B = −0.69, 95% CI = −1.23 to −0.18, p = 0.010
PMID 33213541 · one of two readings recorded this
difference in response prediction by baseline CRT, simpler model
no effect, p = 0.27
B = −0.25, 95% CI = −0.69 to 0.19, p = 0.270
PMID 33213541 · one of two readings recorded this
difference in response prediction by baseline EFT interference, bupropion vs sertraline
modulates, p = 0.007
B = 0.081, 95% CI = 0.027–0.15, p = 0.007
PMID 33213541 · one of two readings recorded this
difference in response prediction by baseline response bias, bupropion vs sertraline
modulates, p = 0.003
B = 11.8, 95% CI = 4.60–20.6, p = 0.003
PMID 33213541 · one of two readings recorded this
difference in response prediction by baseline verbal fluency, bupropion vs sertraline
modulates, p = 0.035
B = 1.01, 95% CI = 0.097–2.00, p = 0.035
PMID 33213541 · one of two readings recorded this
difference in response prediction by early ABRT change, placebo vs sertraline
modulates, p = 0.027
B = 1.11, 95% CI = 0.16–2.12, p = 0.027
PMID 33213541 · one of two readings recorded this
difference in response prediction by early ABRT change, simpler model
unclear, p = 0.052
B = 0.74, 95% CI = 0.018–1.52, p = 0.052
PMID 33213541 · one of two readings recorded this
difference in response prediction by early CRT change, placebo vs sertraline
modulates, p = 0.001
B = 1.71, 95% CI = 0.71–2.79, p = 0.001
PMID 33213541 · one of two readings recorded this
difference in response prediction by early CRT change, simpler model
modulates, p = 0.018
B = 1.03, 95% CI = 0.19–1.91, p = 0.018
PMID 33213541 · one of two readings recorded this
early ABRT change, controls vs placebo non-responders (post-hoc)
no effect, p = 0.76
t(106) = 0.30, p = 0.76, Cohen’s d = 0.06
PMID 33213541 · one of two readings recorded this
early ABRT change, controls vs placebo responders (post-hoc)
no effect, p = 0.168
t(80) = 1.93, p = 0.168, Cohen’s d = 0.42
PMID 33213541 · one of two readings recorded this
early ABRT change, placebo responders vs non-responders (post-hoc)
increases, p = 0.043
t(113) = 2.49, p = 0.043, Cohen’s d = 0.48
PMID 33213541 · one of two readings recorded this
early CRT change, placebo non-responders vs controls (post-hoc)
decreases, p = 0.055
t(117) = −2.38, p = 0.055, Cohen’s d = 0.46
PMID 33213541 · one of two readings recorded this
early CRT change, placebo non-responders vs responders (post-hoc)
decreases, p = 0.019
t(124) = −2.77, p = 0.019, Cohen’s d =0.51
PMID 33213541 · one of two readings recorded this
early CRT change, placebo responders vs controls (post-hoc)
no effect, p = 0.79
t(84) = 0.272, p = 0.79, Cohen’s d = 0.05
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline ABRT (placebo)
decreases, p = 0.025
B = −0.52, 95% CI = −0.97 to -0.07, p = 0.025
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline ABRT (sertraline)
no effect, p = 0.994
B = −0.002, 95% CI = −0.41 to 0.41, p = 0.994
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline CRT (placebo)
decreases, p = 0.011
B = −0.55, 95% CI = −0.97 to -0.13, p = 0.011
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline CRT (sertraline)
no effect, p = 0.392
B = 0.14, 95% CI = −0.18 to 0.47, p = 0.392
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline EFT interference (bupropion)
increases, p = 0.01
B = 0.065, 95% CI = 0.016–0.11, p = 0.010
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline EFT interference (sertraline)
no effect, p = 0.321
B = −0.016, 95% CI = −0.049 to 0.015, p = 0.321
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline response bias, PRT (bupropion after sertraline)
increases, p = 0.008
B = 9.59, 95% CI = 2.46–16.3, p = 0.008
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline response bias, PRT (sertraline after placebo)
no effect, p = 0.249
B = −2.20, 95% CI = −6.27 to 1.35, p = 0.249
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline verbal fluency (bupropion)
unclear, p = 0.067
B = 0.66, 95% CI = −0.046 to 1.37, p = 0.067
PMID 33213541 · one of two readings recorded this
response likelihood vs baseline verbal fluency (sertraline)
no effect, p = 0.259
B = −0.34, 95% CI = −0.97 to 0.24, p = 0.259
PMID 33213541 · one of two readings recorded this
response likelihood vs early ABRT change (placebo)
increases, p = 0.015
B = 0.81, 95% CI = 0.16–1.47, p = 0.015
PMID 33213541 · one of two readings recorded this
response likelihood vs early ABRT change (sertraline)
no effect, p = 0.429
B = −0.29, 95% CI = −1.05 to 0.43, p = 0.429
PMID 33213541 · one of two readings recorded this
response likelihood vs early CRT change (placebo)
increases, p = 0.012
B = 1.05, 95% confidence interval (CI) = 0.23–1.86, p = 0.012
PMID 33213541 · one of two readings recorded this
response likelihood vs early CRT change (sertraline)
decreases, p = 0.037
B = −0.67, 95% CI = −1.32 to -0.06, p = 0.037
PMID 33213541 · one of two readings recorded this
hits: three-way interaction treatment x valence x baseline CIS-R depressive symptoms, fully adjusted
unclear, p = 0.06
adjusted interaction hits ratio = 1.02, 95% CI 1.00–1.05, p = 0.06
PMID 33431087 · one of two readings recorded this
hits: three-way interaction treatment x valence x baseline GAD-7, fully adjusted
no effect, p = 0.47
adjusted interaction hits ratio = 1.01, 95% CI 0.99–1.03, p = 0.47
PMID 33431087 · one of two readings recorded this
negative false alarms, 2 weeks
no effect
2 weeks | 281 | 0.88 (1.14) | 272 | 0.94 (1.13)
PMID 33431087 · one of two readings recorded this
negative false alarms, 6 weeks
no effect
6 weeks | 276 | 0.94 (1.27) | 260 | 1.10 (1.37)
PMID 33431087 · one of two readings recorded this
negative false alarms, baseline
Baseline | 291 | 0.87 (1.16) | 284 | 0.91 (1.27)
PMID 33431087 · one of two readings recorded this
negative hits, 2 weeks
no effect
2 weeks | 281 | 2.09 (1.45) | 272 | 2.07 (1.49)
PMID 33431087 · one of two readings recorded this
negative hits, 6 weeks
no effect
6 weeks | 275 | 2.04 (1.70) | 259 | 2.00 (1.62)
PMID 33431087 · one of two readings recorded this
negative hits, baseline (word recall)
Baseline | 291 | 1.93 (1.38) | 284 | 2.07 (1.50)
PMID 33431087 · one of two readings recorded this
negative hits: interaction treatment x time (2 vs 6 weeks), fully adjusted
no effect, p = 0.95
adjusted interaction hits ratio = 1.01, 95% CI 0.85–1.19, p = 0.95
PMID 33431087 · one of two readings recorded this
negative hits ratio, fully adjusted (2 and 6 weeks)
no effect, p = 0.85, n = 574
Fully adjusted b | 574 | 0.98 (0.90–1.06) | 0.56 | 574 | 0.99 (0.91–1.08) | 0.85
PMID 33431087 · one of two readings recorded this
negative hits ratio, partially adjusted (2 and 6 weeks)
no effect, p = 0.85, n = 574
Partially adjusted a | 574 | 0.99 (0.91–1.07) | 0.73 | 574 | 0.99 (0.91–1.08) | 0.85
PMID 33431087 · one of two readings recorded this
negative hits ratio, sertraline vs placebo
no effect
High depressive symptoms | 2.12 (1.37) | 2.16 (1.42) | 2.06 (1.56) | 1.95 (1.50) | 2.10 (1.30) | 2.04 (1.51) | 1.07 (0.93–1.23)
PMID 33431087 · one of two readings recorded this
negative hits ratio, sertraline vs placebo
no effect
Low depressive symptoms | 1.86 (1.43) | 1.99 (1.50) | 2.15 (1.91) | 2.10 (1.46) | 1.86 (1.74) | 1.85 (1.47) | 0.92 (0.77–1.10)
PMID 33431087 · one of two readings recorded this
negative hits ratio, sertraline vs placebo
no effect
Moderate depressive symptoms | 1.74 (1.31) | 2.09 (1.43) | 1.91 (1.66) | 2.19 (1.55) | 2.27 (1.36) | 2.13 (1.89) | 0.95 (0.80–1.12)
PMID 33431087 · one of two readings recorded this
negative hits ratio, unadjusted (2 and 6 weeks)
no effect, p = 0.81, n = 576
Unadjusted | 576 | 0.98 (0.89–1.08) | 0.66 | 576 | 0.99 (0.89–1.10) | 0.81
PMID 33431087 · one of two readings recorded this
number of positive and negative personality words correctly recalled (hits) after the emotional categorisation task (ECAT) free recall, at 2 and 6 weeks, sertraline vs placebo, Poisson mixed models
no effect, adjusted positive hits ratio 0.98, 95% CI 0.90-1.06, p = 0.56
Not recorded as a finding: this platform holds no node for the endpoint
We found no evidence that treatment allocation was associated with positive hits (adjusted hits ratio = 0.98, 95% CI 0.90–1.06, p = 0.56; Table 3).
PMID 33431087 · one of two readings recorded this
number of positive and negative personality words correctly recalled (hits) on an incidental recall task after the emotional categorisation task, Poisson mixed models, sertraline vs placebo at 2 and 6 weeks
no effect, adjusted hits ratio 0.98, 95% CI 0.90-1.06 for positive hits, p = 0.56
Not recorded as a finding: this platform holds no node for the endpoint
We found no evidence that treatment allocation was associated with positive hits (adjusted hits ratio = 0.98, 95% CI 0.90–1.06, p = 0.56; Table 3).
PMID 33431087 · one of two readings recorded this
positive false alarms, 2 weeks
no effect
2 weeks | 281 | 1.60 (1.61) | 272 | 1.55 (1.45)
PMID 33431087 · one of two readings recorded this
positive false alarms, 6 weeks
no effect
6 weeks | 276 | 1.30 (1.49) | 260 | 1.55 (1.67)
PMID 33431087 · one of two readings recorded this
positive false alarms, baseline
Baseline | 291 | 1.29 (1.42) | 284 | 1.33 (1.37)
PMID 33431087 · one of two readings recorded this
positive hits, 2 weeks
no effect
2 weeks | 281 | 3.11 (2.00) | 272 | 2.95 (1.98)
PMID 33431087 · one of two readings recorded this
positive hits, 6 weeks
no effect
6 weeks | 276 | 2.31 (1.62) | 260 | 2.32 (1.60)
PMID 33431087 · one of two readings recorded this
positive hits, baseline (word recall)
Baseline | 291 | 3.03 (1.73) | 284 | 2.88 (1.77)
PMID 33431087 · one of two readings recorded this
positive hits: interaction treatment x time (2 vs 6 weeks), fully adjusted
no effect, p = 0.18
adjusted interaction hits ratio = 1.11, 95% CI 0.96–1.28, p = 0.18
PMID 33431087 · one of two readings recorded this
positive hits ratio, fully adjusted (2 and 6 weeks)
no effect, p = 0.56, n = 574
Fully adjusted b | 574 | 0.98 (0.90–1.06) | 0.56 | 574 | 0.99 (0.91–1.08) | 0.85
PMID 33431087 · one of two readings recorded this
positive hits ratio, partially adjusted (2 and 6 weeks)
no effect, p = 0.73, n = 574
Partially adjusted a | 574 | 0.99 (0.91–1.07) | 0.73 | 574 | 0.99 (0.91–1.08) | 0.85
PMID 33431087 · one of two readings recorded this
positive hits ratio, sertraline vs placebo
no effect
High depressive symptoms | 3.12 (1.74) | 3.29 (2.00) | 2.40 (1.66) | 2.67 (1.57) | 2.86 (1.94) | 2.31 (1.63) | 1.00 (0.88–1.13)
PMID 33431087 · one of two readings recorded this
positive hits ratio, sertraline vs placebo
no effect
Low depressive symptoms | 3.12 (1.77) | 3.18 (2.10) | 2.45 (1.69) | 3.02 (1.97) | 2.87 (2.05) | 2.26 (1.48) | 0.92 (0.79–1.06)
PMID 33431087 · one of two readings recorded this
positive hits ratio, sertraline vs placebo
no effect
Moderate depressive symptoms | 2.80 (1.65) | 2.78 (1.86) | 2.01 (1.45) | 3.00 (1.76) | 3.19 (1.94) | 2.43 (1.70) | 1.05 (0.90–1.23)
PMID 33431087 · one of two readings recorded this
positive hits ratio, unadjusted (2 and 6 weeks)
no effect, p = 0.66, n = 576
Unadjusted | 576 | 0.98 (0.89–1.08) | 0.66 | 576 | 0.99 (0.89–1.10) | 0.81
PMID 33431087 · one of two readings recorded this
total hits: interaction treatment x time, fully adjusted
no effect, p = 0.25
adjusted interaction between treatment allocation and time hits ratio = 1.07, 95% CI 0.96–1.19, p = 0.25
PMID 33431087 · one of two readings recorded this
total hits: interaction treatment x valence (Model 2), fully adjusted
no effect, p = 0.87, n = 574
Fully adjusted b | 574 | 0.98 (0.92–1.05) | 0.61 | 1.01 (0.90–1.13) | 0.87
PMID 33431087 · one of two readings recorded this
total hits: interaction treatment x valence (Model 2), partially adjusted
no effect, p = 0.87, n = 574
Partially adjusted a | 574 | 0.99 (0.93–1.06) | 0.75 | 1.01 (0.90–1.13) | 0.87
PMID 33431087 · one of two readings recorded this
total hits: interaction treatment x valence (Model 2), unadjusted
no effect, p = 0.82, n = 576
Unadjusted | 576 | 0.99 (0.90–1.08) | 0.74 | 1.01 (0.91–1.13) | 0.82
PMID 33431087 · one of two readings recorded this
total hits: three-way interaction treatment x valence x time, fully adjusted
no effect, p = 0.51
adjusted interaction between treatment allocation, valence and time hits ratio = 0.93, 95% CI 0.74–1.15, p = 0.51
PMID 33431087 · one of two readings recorded this
total hits: treatment effect (Model 1), fully adjusted
no effect, p = 0.61, n = 574
Fully adjusted b | 574 | 0.98 (0.92–1.05) | 0.61 | 1.01 (0.90–1.13) | 0.87
PMID 33431087 · one of two readings recorded this
total hits: treatment effect (Model 1), partially adjusted
no effect, p = 0.75, n = 574
Partially adjusted a | 574 | 0.99 (0.93–1.06) | 0.75 | 1.01 (0.90–1.13) | 0.87
PMID 33431087 · one of two readings recorded this
total hits: treatment effect (Model 1), unadjusted
no effect, p = 0.74, n = 576
Unadjusted | 576 | 0.99 (0.90–1.08) | 0.74 | 1.01 (0.91–1.13) | 0.82
PMID 33431087 · one of two readings recorded this
CGI-I minimally improved, post-treatment
Minimally improved | 16.3 | 18.2 | 13 | 17.5
PMID 34463234 · one of two readings recorded this
CGI-I much improved, post-treatment and follow-up
Much improved | 32.7 | 40 | 17.4 | 27.5
PMID 34463234 · one of two readings recorded this
CGI-I no change, post-treatment
No change | 6.1 | 4.5 | 2.2 | 5
PMID 34463234 · one of two readings recorded this
CGI-I very much improved, follow-up
no effect, p = 0.73, n = 85
Very much improved | 44.9 | 36.4 | χ2(3, N = 94) = 0.999, p = 0.80 | 67.4 | 50 | χ2(3, N = 85) = 0.12, p = 0.73
PMID 34463234 · one of two readings recorded this
CGI-I very much improved, post-treatment
no effect, p = 0.8, n = 94
Very much improved | 44.9 | 36.4 | χ2(3, N = 94) = 0.999, p = 0.80 | 67.4 | 50 | χ2(3, N = 85) = 0.12, p = 0.73
PMID 34463234 · one of two readings recorded this
emotional outbursts (SSRI side effects checklist, weekly)
decreases, p = 0.031, n = 97
emotional outbursts, χ2(1, N = 97) = 4.67, p = 0.031
PMID 34463234 · one of two readings recorded this
irritability symptoms (SSRI side effects checklist, weekly)
decreases, p = 0.026, n = 97
Children in the CBT + PBO condition reported significantly greater mean irritability symptoms, χ2(1, N = 97) = 4.98, p = 0.026
PMID 34463234 · one of two readings recorded this
medication adherence (pill counts and diaries)
children and families showed excellent adherence to the medication treatment protocol (CBT + SERT: 92.4%; CBT + PBO: 95.67%)
PMID 34463234 · one of two readings recorded this
remission of all anxiety diagnoses, follow-up
no effect, p = 0.73, n = 85
Anxiety diagnoses | 61.2 | 51.1 | χ2(1, N = 94) = 0.98, p = 0.32, Cohen's d = 0.21 | 65.2 | 61.5 | χ2(1, N = 85) = 0.12, p = 0.73, Cohen's d = 0.08
PMID 34463234 · one of two readings recorded this
remission of all anxiety diagnoses, post-treatment
no effect, p = 0.32, n = 94
Anxiety diagnoses | 61.2 | 51.1 | χ2(1, N = 94) = 0.98, p = 0.32, Cohen's d = 0.21 | 65.2 | 61.5 | χ2(1, N = 85) = 0.12, p = 0.73, Cohen's d = 0.08
PMID 34463234 · one of two readings recorded this
remission of primary anxiety disorder and of all anxiety diagnoses (clinical severity rating below 4 on a modified ADIS-IV-C/P) at post-treatment and 6-month follow-up, CBT plus sertraline vs CBT plus placebo in youth
no effect, no significant difference in remission rates between CBT + SERT and CBT + PBO
Not recorded as a finding: this platform holds no node for the endpoint
At post and follow-up, there were no significant differences across conditions in remission rates based on primary disorder or all anxiety disorders (see Table 3 and Fig. 2).
PMID 34463234 · one of two readings recorded this
remission of primary anxiety disorder and of all anxiety disorders (clinical severity rating below 4 on ADIS-IV-C/P) at post-treatment and 6 months; SCAS child and parent anxiety symptoms; SMFQ depressive symptoms; CALIS life interference
no effect, no significant differences across conditions in remission rates, CBT plus sertraline vs CBT plus placebo
Not recorded as a finding: this platform holds no node for the endpoint
At post and follow-up, there were no significant differences across conditions in remission rates based on primary disorder or all anxiety disorders (see Table 3 and Fig. 2).
PMID 34463234 · one of two readings recorded this
remission of primary anxiety disorder, follow-up
no effect, p = 0.63, n = 85
Primary | 71.4 | 68.9 | χ2(1, N = 94) = 0.07, p = 0.79, Cohen's d = 0.05 | 73.9 | 69.2 | χ2(1, N = 85) = 0.23, p = 0.63, Cohen's d = 0.10
PMID 34463234 · one of two readings recorded this